RT Journal Article
SR Electronic
T1 Regional variation in cardiovascular genes enables a tractable genome editing strategy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.03.22271786
DO 10.1101/2022.03.03.22271786
A1 Krysov, Vikki A.
A1 Wilson, Rachel H.
A1 Ten, Nicholas S.
A1 Youlton, Nathan
A1 De Jong, Hannah N.
A1 Sutton, Shirley
A1 Huang, Yong
A1 Reuter, Chloe
A1 Grove, Megan E.
A1 Wheeler, Matthew T.
A1 Ashley, Euan A.
A1 Parikh, Victoria N.
YR 2022
UL http://medrxiv.org/content/early/2022/03/08/2022.03.03.22271786.abstract
AB Recent rise in the number and therapeutic potential of genome engineering technologies has generated excitement in cardiovascular genetics. One significant barrier to their implementation is costly and time consuming reagent development for novel unique variants. Prior data have illuminated the potential for regional clustering of disease-causing genetic variants in known and potential novel functional protein domains. We hypothesized that most cardiovascular disease-relevant genes in ClinVar would display regional variant clustering, and that multiple variants within a regional hotspot could be targeted with limited prime editing reagents. We collated 2,471 high confidence pathogenic or likely pathogenic (P/LP) missense and truncating variants from 111 cardiovascular disease genes. We then defined a regional clustering index (RCI), the percent of P/LP variants in a given gene located within a pre-specified window around each variant. At a window size commensurate with maximally reported prime editing extension length, 78bp, we found that missense variants displayed a higher mean RCI than truncating variants. We next identified genes particularly attractive for pathogenic hotspot-targeted prime editing with at least 20 P/LP variants and observed that the mean RCI in missense variants remained higher than for truncating variants and for rare variants observed in the same genes in gnomAD (Mean±SD RCI78bp: P/LP ClinVar Missense=5.2±5.9%; P/LP ClinVar Truncating=2.1±3.2%, gnomAD Missense=2±3.2%, gnomAD Truncating=1.1±2.4%. p<2.2e-16; ANOVA with post hoc Bonferroni correction). Further, we tested the feasibility of prime editing for multiple variants in a single hotspot in KCNH2, a gene with a high mean missense variant RCI. Sixty variants were induced in this hotspot in HEK293 cells with CRISPR-X. Correction of these variants was attempted with prime editing using two overlapping prime editing guide RNA extensions. The mean prime editing efficiency across CRISPR-X-enriched variants within this hotspot was 57±27%, including 3 P/LP variants. These data underscore the utility of pathogenic variant hotspots in the diagnosis and treatment of inherited cardiovascular disease.Competing Interest StatementVNP serves on the SAB of Biomarin, Inc and has sponsored research funding from Biomarin, Inc. EAA serves on the board of AstraZeneca, Inc., is a founder of Personalis, Inc and DeepCell. MTW has minor ownership in Personalis, and receives research support from Bristol Myers Squibb, Pfizer and Novartis.Funding StatementThis work was funded by NHLBI K08HL14318503 and R01HL14484302, the Sarnoff Cardiovascular Research Foundation, the John Taylor Babbitt Foundation, and the Stanford School of Medicine Medical Scholars Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors